Highlights
- Aficamten effectively reduces hypercontractility in nonobstructive hypertrophic cardiomyopathy (nHCM), improving symptomatic burden and cardiac function.
- The phase 3 ACACIA-HCM trial established aficamten’s superiority over placebo in multiple clinically meaningful endpoints at 36 weeks.
- Complementary phase 2 (REDWOOD-HCM) and ongoing phase 3 (FOREST-HCM) studies support favorable safety and sustained efficacy profiles.
- Integrated responder analyses demonstrate that aficamten yields multidimensional improvements including exercise capacity, left atrial remodeling, diastolic enhancement, and natriuretic peptide reduction.
